12:00 AM
Jan 31, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

OraRinse: Began Phase II study

Access Pharmaceuticals Inc. (AXCS), Dallas, Texas
Product: OraRinse
Business: Autoimmune/Inflammation, Cancer
Therapeutic category: Cytokine production, Adjunct...

Read the full 70 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >